Show simple item record

dc.contributor.authorDavis, JE
dc.contributor.authorHandunnetti, SM
dc.contributor.authorLudford-Menting, M
dc.contributor.authorSharpe, C
dc.contributor.authorBlombery, P
dc.contributor.authorAnderson, MA
dc.contributor.authorRoberts, AW
dc.contributor.authorSeymour, JF
dc.contributor.authorTam, CS
dc.contributor.authorRitchie, DS
dc.contributor.authorKoldej, RM
dc.date.accessioned2021-05-10T00:27:00Z
dc.date.available2021-05-10T00:27:00Z
dc.date.issued2020-10-13
dc.identifierpii: 464131
dc.identifier.citationDavis, J. E., Handunnetti, S. M., Ludford-Menting, M., Sharpe, C., Blombery, P., Anderson, M. A., Roberts, A. W., Seymour, J. F., Tam, C. S., Ritchie, D. S. & Koldej, R. M. (2020). Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. BLOOD ADVANCES, 4 (19), pp.4849-4859. https://doi.org/10.1182/bloodadvances.2020002810.
dc.identifier.issn2473-9529
dc.identifier.urihttp://hdl.handle.net/11343/273358
dc.description.abstractCombination venetoclax plus ibrutinib for the treatment of mantle cell lymphoma (MCL) has demonstrated efficacy in the relapsed or refractory setting; however, the long-term impact on patient immunology is unknown. In this study, changes in immune subsets of MCL patients treated with combination venetoclax and ibrutinib were assessed over a 4-year period. Multiparameter flow cytometry of peripheral blood mononuclear cells showed that ≥12 months of treatment resulted in alterations in the proportions of multiple immune subsets, most notably CD4+ and CD8+ effector and central memory T cells and natural killer cells, and normalization of T-cell cytokine production in response to T-cell receptor stimulation. Gene expression analysis identified upregulation of multiple myeloid genes (including S100 and cathepsin family members) and inflammatory pathways over 12 months. Four patients with deep responses stopped study drugs, resulting in restoration of normal immune subsets for all study parameters except myeloid gene/pathway expression, suggesting long-term combination venetoclax and ibrutinib irreversibly affects this population. Our findings demonstrate that long-term combination therapy is associated with immune recovery in MCL, which may allow responses to subsequent immunotherapies and suggests that this targeted therapy results in beneficial impacts on immunological recovery. This trial was registered at www.clinicaltrials.gov as #NCT02471391.
dc.languageEnglish
dc.publisherAMER SOC HEMATOLOGY
dc.titleImmune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy
dc.typeJournal Article
dc.identifier.doi10.1182/bloodadvances.2020002810
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.affiliation.departmentCentre for Cancer Research
melbourne.affiliation.departmentMedicine (RMH)
melbourne.affiliation.departmentMedicine (St Vincent's)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleBlood Advances
melbourne.source.volume4
melbourne.source.issue19
melbourne.source.pages4849-4859
melbourne.elementsid1479874
melbourne.openaccess.urlhttps://doi.org/10.1182/bloodadvances.2020002810
melbourne.openaccess.statusPublished version
melbourne.contributor.authorLudford-Menting, Mandy
melbourne.contributor.authorSeymour, John
melbourne.contributor.authorTam, Constantine
melbourne.contributor.authorRitchie, David
melbourne.contributor.authorRoberts, Andrew
melbourne.contributor.authorDavis, Joanne
melbourne.contributor.authorKoldej, Rachel
melbourne.contributor.authorHandunnetti, Sasanka
melbourne.contributor.authorAnderson, Mary Ann
melbourne.contributor.authorBlombery, Piers
dc.identifier.eissn2473-9537
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record